Business Wire

Korian Benelux Future-Proofs its Residential Care Centers with Juniper Networks’ AI-driven Enterprise Solutions

23.5.2023 10:00:00 EEST | Business Wire | Press release

Share

Juniper Networks® (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Korian Benelux, part of a major European healthcare and long-term elderly care organization, selected Juniper’s AI-driven enterprise solutions, including wireless and wired access, to optimize network performance and reliability and deliver personalized care for its residents.

More than 11 thousand Korian employees provide care for approximately 15 thousand residents in 173 locations in The Netherlands and Belgium. Korian was drawn to the Mist AI engine with cloud-hosted operations to give its IT team greater insights into user experiences and better troubleshooting for connected medical Wi-Fi devices and phones. The real-time insights, provided by Juniper Mist Wired Assurance, Juniper Mist Wireless Assurance and the Marvis™ Virtual Network Assistant, have simplified troubleshooting at the customer, device and site level for better service quality. By leveraging Mist AI, the Juniper solution delivers customizable service levels and actionable recommendations to proactively fix issues, often before users are impacted. As a result, users experience a more reliable network infrastructure with less downtime, due to the Juniper Mist AI predictive approach. Centralized configuration and zero-touch provisioning simplify onboarding new Juniper access points and switches as facilities are updated. When Korian does a renovation, the network can be installed in one day, compared to two days with their previous wireless solution.

Staying connected to families and friends is important to the well-being of Korian’s residents and short-term recovery patients, whether they like to call, video chat or email. Residents can use tablets in their rooms to watch movies, listen to their favorite music and call the nursing staff if they need help. Voice communications are loud and clear. Families and friends have guest Wi-Fi when they come to visit.

Korian staff have fast, responsive access to their long-term care, clinical and administrative applications, so they can stay productive and focused on patient care. Smart medical devices have the more reliable connectivity necessary for Korian to provide optimal care.

The organization adopted Juniper Wireless Access Points and Wireless Assurance driven by Mist AI to deliver better resident engagement, coupled with industry-leading Wi-Fi that is both more predictable and more reliable. In addition, Juniper Networks EX Series Switches and Juniper Mist Wired Assurance provide high-performance, more secure access to the access points and other wired devices. Juniper was named a Leader in the 2022 Gartner® Magic Quadrant™ for Enterprise Wired and Wireless LAN Infrastructure.

Korian Benelux Group worked with Nomios, a Juniper Elite Plus partner, to create the optimal network architecture, focusing on network design, validation and testing to ensure that the Juniper solutions met strategic and technical goals.

Supporting Quotes:

“With our new network, our nursing staff have resilient access to medical and administrative applications. Computers on wheels and other smart medical equipment are always connected. Residents and their families can now easily connect to the Wi-Fi. IT has clear visibility into service level expectations and what we’re actually delivering. With Juniper Mist, we can see any Wi-Fi problems ourselves immediately, instead of waiting for nursing staff to tell us. Ultimately, we spend less time troubleshooting, and that frees up our time for more strategic priorities.”

- Christoph Van Doren, ICT Director, Korian Benelux

“Healthcare organizations are constantly looking to leverage innovative technology to deliver a high-touch experience for residents, guests and staff. The network plays a vital role at Korian by keeping its technology infrastructure healthy. It allows them to simply scale and support new applications and technologies that can assist in driving better resident outcomes and experiences.”

- Gos Hein van de Wouw, Vice President, Enterprise, EMEA, Juniper Networks

Additional Resources:

About Juniper Networks

Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations:
Pelin Murphy
Juniper Networks
+44 (0) 1372 385 686
pelin@juniper.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye